Record three in five HIV-carriers now have access to drugs: UN

Almost three in five people infected with HIV, or 21.7 million globally, took antiretroviral therapy in 2017 -- a new record for anti-AIDS drug access, the UN's HIV/AIDS agency said today.

There were 36.9 million people living with the immune system-attacking virus in 2017, of whom 15.2 million were not getting the drugs they need -- the lowest number since the epidemic exploded, UNAIDS reported.

Hailing progress in curbing new infections and deaths, the agency nevertheless lamented the mounting human toll: almost 80 million infections and 35.4 million lives lost since the first cases became known in the early 1980s.

Progress made to date risks being halted, even reversed, if funding and world attention is allowed to dwindle, the agency warned.

"We are short USD 7 billion (six billion euros) per year to maintain our results and to achieve our objectives for 2020," UNAIDS executive director Michel Sidibe told AFP.

"Without these resources, there is a big risk of the epidemic rebounding, of an increase in mortality due to AIDS," he said.

In 2017, about USD 20.6 billion was available for AIDS programmes in low- and middle-income countries which funded about 56 percent from their own budgets, said the report.

Under Donald Trump, the US administration -- a major funder of AIDS programmes historically, has threatened to cut spending.

The UN goal is for 90 per cent of all HIV-positive people to know their status by 2020. Of these, at least 90 per cent must receive ART, and the HIV virus be suppressed in 90 percent of those.

Assessing progress towards the target, UNAIDS said 1.8 million people became newly infected with HIV in 2017.

This was down from about 1.9 million the year before, and 3.4 million at the peak of the epidemic in 1996.

Deaths declined from 990,000 to 940,000 year-on-year, compared to 1.9 million in 2005 and 1.4 million in 2010.

The number of people on antiretroviral therapy (ART) grew from 19.4 million in 2016 to 21.7 million last year -- up from a mere 611,000 in the year 2000 and 2.1 million in 2005, said the report released in the run-up to the International AIDS Conference in Amsterdam next week.

This helped boost the number of people living with the virus from 36.3 million in 2016 to 36.9 million last year.

Despite more than three decades of research, there is no cure or vaccine and HIV-positive people have to take lifelong treatment that can be expensive and have nasty side-effects.

ART inhibits the virus and can limit its spread between people -- mainly through sex -- but does not kill it.

UNAIDS reported large variation between world regions in the battle against the killer virus.

In the Middle East and north Africa, for example, less than a third of people with HIV have access to ARV, only 36 percent of those in eastern Europe and central Asia, and 40 per cent in west and central Africa.

For west and central Europe and North America, the number is 78 per cent, with about 1.7 million out of 2.2 million infected people on ARV, said UNAIDS.

In east and southern Africa -- home to 53 per cent of people living with HIV in the world -- deaths declined by 42 per cent from 2010 to 2017, thanks largely to the widespread rollout of treatment.

However, "there has been no reduction in AIDS-related mortality in eastern Europe and central Asia since 2010, and deaths from AIDS-related illness increased by 11 per cent in the Middle East and North Africa," cautioned the report.

"Some countries continue to concern us, such as Nigeria which accounts for about half of all new infections in west Africa," said Sidibe.

In Russia, he added, the epidemic "is becoming widespread. While it was concentrated among people who inject drugs, it is affecting the general population more and more."